(0)
IRVINE, CA / ACCESSWIRE / March 10, 2021 / Odyssey Group International, Inc. (OTCQB:ODYY) (the Company or Odyssey ), a technology and asset acquisition company focused on developing unique, life-saving medical products, is pleased to announce that Dr. Jake VanLandingham, Odyssey s Vice President of Drug Development and the lead scientist developing PRV-002 will be joining Brett Favre to discuss the impact of concussions and the importance of this novel concussion treatment on NewsNation Now s The Donlon Report. The segment is expected to air at 7:30PM Eastern Time on March 10, 2021. I am pleased that PRV-002, our pre-clinical stage concussion treatment continues to receive so much attention from the media, said Dr. Jake VanLandingham. We look forward to continuing development of the drug through the initiation of our upcoming human clinical trials.